Topical Losartan for Treating Corneal Fibrosis (Haze): First Clinical Experience.
J Refract Surg
; 38(11): 741-746, 2022 Nov.
Article
em En
| MEDLINE
| ID: mdl-36367262
ABSTRACT
PURPOSE:
To report the first clinical experience with topical losartan for treating a case of severe corneal haze after complicated laser in situ keratomileusis (LASIK).METHODS:
A 36-year-old woman presented with corneal haze in the left eye after femtosecond laser-assisted LASIK. The left eye had flap dislocation and significant striae, which had been re-lifted. Uncorrected distance visual acuity (UDVA) was 20/200 and corrected distance visual acuity was 20/30 in the left eye at the first presentation, 52 days after the first procedure. A dense layer of subepithelial opacity (haze) was noted in the left cornea. The patient elected to start the off-label treatment with topical losartan 0.8 mg/mL six times per day.RESULTS:
Four and one-half months after initiating topical losartan, UDVA improved to 20/30 and CDVA improved to 20/25 in the left eye. A significant reduction of corneal haze was observed at the slit lamp and using Scheimpflug corneal tomography (Pentacam AXL; Oculus Optikgeräte GmbH) and anterior segment optical coherence tomography (Revo NX 130; Optopol).CONCLUSIONS:
Losartan is an inhibitor of transforming growth factor-ß signaling. Topical treatment is promising to treat corneal haze formation after corneal injuries, chemical burns, and surgeries. Further clinical studies are needed to optimize losartan dosages and treatment durations. [J Refract Surg. 2022;38(11)741-746.].
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Doenças da Córnea
/
Opacidade da Córnea
/
Ceratomileuse Assistida por Excimer Laser In Situ
Idioma:
En
Ano de publicação:
2022
Tipo de documento:
Article